The investigational PAM inhibitor extends progression-free survival from 5 to 7 months in patients with advanced, PIK3CA wild ...
A Danish registry study finds no substantial differences in the 5-year risk for first cancers between three biologics in patients with psoriasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback